Cargando…
Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function
Patients with chronic pain syndromes, such as those with painful peripheral neuropathy due to diabetes mellitus, have limited treatment options and suffer ongoing attrition of their quality of life. Safer and more effective treatment options are needed. One therapeutic approach encompasses phenotypi...
Autores principales: | Jain, Sunil M., Balamurugan, Ramanathan, Tandon, Monika, Mozaffarian, Neelufar, Gudi, Girish, Salhi, Yacine, Holland, Robert, Freeman, Roy, Baron, Ralf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100440/ https://www.ncbi.nlm.nih.gov/pubmed/34490850 http://dx.doi.org/10.1097/j.pain.0000000000002470 |
Ejemplares similares
-
Transient Receptor Potential Ankyrin 1 Receptor Activation In Vitro and In Vivo by Pro-tussive Agents: GRC 17536 as a Promising Anti-Tussive Therapeutic
por: Mukhopadhyay, Indranil, et al.
Publicado: (2014) -
Request for additional beam time for 1994 for ISC/P42 and ISC/P48, (ISC 330 and ISC 331): use of radioactive ion beams for biomedical research
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1994) -
Role of transient receptor potential ankyrin 1 channels in Alzheimer’s disease
por: Lee, Kuan-I, et al.
Publicado: (2016) -
Transient Receptor Potential Ankyrin 1 Mediates Hypoxic Responses in Mice
por: Chen, Sichong, et al.
Publicado: (2020) -
Function and therapeutic potential of transient receptor potential ankyrin 1 in fibrosis
por: Wei, Yicheng, et al.
Publicado: (2022)